Quick Answer
Jazz Pharmaceuticals plc reported Net Income of -$356.15 million for fiscal year 2025.
Jazz Pharmaceuticals plc Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$356.15M | -163.6% |
| 2024 | $560.12M | +35.0% |
| 2023 | $414.83M | +285.1% |
| 2022 | -$224.06M | +32.0% |
| 2021 | -$329.67M | -238.2% |
| 2020 | $238.62M | -54.4% |
| 2019 | $523.37M | +17.1% |
| 2018 | $447.10M | -8.4% |
| 2017 | $487.85M | +22.9% |
| 2016 | $396.83M | +20.4% |
| 2015 | $329.54M | +464.4% |
| 2014 | $58.39M | -73.0% |
| 2013 | $216.31M | -25.0% |
| 2012 | $288.59M | +130.9% |
| 2011 | $124.98M | +281.3% |
| 2010 | $32.78M | +579.5% |
| 2009 | -$6.84M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $251.41M | +16.9% | +135.0% |
| June 30, 2025 | -$718.47M | -526.2% | -676.4% |
| March 31, 2025 | -$92.54M | -533.1% | -143.0% |
| September 30, 2024 | $215.06M | +46.5% | +27.6% |
| June 30, 2024 | $168.57M | +61.4% | +1253.2% |
| March 31, 2024 | -$14.62M | -121.1% | -110.0% |
| September 30, 2023 | $146.82M | +847.3% | +40.6% |
| June 30, 2023 | $104.44M | +201.3% | +50.4% |
- Jazz Pharmaceuticals plc showed a decrease of -163.6% in Net Income compared to the prior fiscal year.
- Over the 2009–2025 period, Jazz Pharmaceuticals plc’s net income has declined by 5109.9% (from -$6.84 million to -$356.15 million).
- The most recent figure is from Jazz Pharmaceuticals plc’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: